Free Trial
NASDAQ:IMNM

Immunome Q2 2023 Earnings Report

Immunome logo
$7.63 -0.87 (-10.24%)
Closing price 04:00 PM Eastern
Extended Trading
$7.70 +0.07 (+0.85%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$4.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunome's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunome Earnings Headlines

Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Immunome initiated with a Buy at Lake Street
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat